May 23, 2022
Tokyo-based biotech Healios’ investigational off-the-shelf somatic stem cell therapy MultiStem (HLCM051) failed to meet the primary endpoint in a Japanese PII/III trial for the treatment of ischemic stroke, an indication subject to its sakigake designation. According to topline results obtained...read more